The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 873-880

  Dbaibo, Ghassan ^a   Macalalad, Noel ^b   Aplasca De Los Reyes, Mari Rose ^c   Dimaano, Efren ^d   Bianco, Veronique ^e   Baine, Yaela ^f   Miller, Jacqueline ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b De La Salle Health Sciences Institute   (Philippines)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d San Lazaro Hospital   (Philippines)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f GLAXOSMITHKLINE   (United States)

Author keywords

ACWY TT vaccine; Adult; Bactericidal activity; Conjugate vaccine; Immunogenicity; Neisseria meningitidis; Safety; Tetravalent meningococcal vaccine; Vaccine

Indexed keywords

ACWY TT VACCINE; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CARRIER PROTEIN; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; NEW DRUG; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MANUFACTURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MENINGOCOCCOSIS; NORMAL HUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; DRUG TOXICITY; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; YOUNG ADULT;

EID: 84864042036     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20211     Document Type: Article

References (35)

1. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004;23(Suppl):S274-9; PMID:15597069
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
3. World Health Organization. Epidemic and pandemic alert and response (EPR). Meningococcal disease in the Philippines - update 2 2005 [Internet]. [cited 2009 Dec 30]; Available from: http: //www.who.int/csr/don/2005-01-28a/en/ index.html
4. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679-83; PMID: 12627350; http://dx.doi.org/10.1086/ 367858
5. Hausdorff WP, Hajjeh R, Al-Mazrou A, Shibl A, Soriano-Gabarro M, Middle East & North Africa Vaccine-Preventable Diseases Regional Advisory Group. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region-current status and needs. Vaccine 2007; 25:1935-44; PMID:17241707; http://dx.doi.org/10.1016/j.vaccine.2006.11.018
6. Lingappa JR, Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-71; PMID:12781005
7. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi.org/10.1086/649209
8. Gagneux SP, Hodgson A, Smith TA, Wirth T, Ehrhard I, Morelli G, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002; 185:618-26; PMID:11865418; http://dx.doi.org/10.1086/ 339010
9. Boisier P, Nicolas P, Djibo S, Taha M-K, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63; PMID: 17278055; http://dx.doi.org/10.1086/511646
10. Decosas J, Koama J-BT. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002; 2:763-5; PMID: 12467693; http://dx.doi.org/10.1016/S1473-3099(02)00455-3
11. Collard JM, Maman Z, Yacouba H, Djibo S, Nicolas P, Jusot JF, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 2010;16:1496-8; PMID:20735947; http://dx.doi.org/10.3201/eid1609.100510
12. Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J Infect Public Health 2010; 3:143-51; PMID:21126718; http://dx.doi.org/10.1016/j.jiph.2010.09.008
13. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002; 77:331-9; PMID:12385146
14. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-4; PMID:9728562; http://dx.doi.org/10.1086/515346
15. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011;10:307-22; PMID:21434799; http://dx.doi.org/10.1586/erv.11.8
16. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(Suppl 1):S58-67; PMID: 11587814; http://dx.doi.org/10.1016/S0264-410X(01)00299-7
17. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWYTT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075
18. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53; PMID:19887137; http://dx.doi.org/10.1016/j. vaccine.2009.10.064
19. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9
20. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965; http://dx.doi.org/10.1016/j.vaccine. 2011.03.043
21. Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/ INF.0b013e31820e6e02
22. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009
23. Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698; http://dx.doi.org/10.4161/hv.7.2.14068
24. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
25. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904
26. Campbell JD, Edelman R, King JC, Jr., Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharidediphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186:1848-51; PMID: 12447774; http://dx.doi.org/10.1086/345763
27. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi M-P, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25(Suppl 1):A101-7; PMID:17532101; http://dx.doi.org/10.1016/j.vaccine.2007.04.050
28. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009;16:1810-5; PMID:19812260; http://dx.doi.org/10.1128/CVI. 00207-09
29. Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM (197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14:e868-75; PMID:20655261; http://dx.doi.org/10.1016/j.ijid.2010.03.017
30. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293-304; PMID:21675889; http://dx.doi.org/10.1056/ NEJMoa1003812
31. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13; PMID:16203934; http://dx.doi.org/10.1001/archpedi.159.10.907
32. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657-63; PMID:19895922; http://dx.doi.org/10.1016/j.vaccine.2009.10.104
33. Wassilak S, Murphy TV, Roper M, Orenstein W. Tetanus toxoid. In: Vaccines. Philadelphia: Saunders Elsevier; 2004. p. 745-824.
34. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649
35. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-44; PMID:6345548; http://dx.doi.org/10.1016/S0092-1157(83) 80038-9